NovaBay Pharmaceuticals, Inc.
NBY
$1.03
$0.4371.67%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.99% | -2.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.99% | -24.93% | |||
| Operating Income | 29.99% | -109.54% | |||
| Income Before Tax | 41.02% | -151.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.02% | -151.70% | |||
| Earnings from Discontinued Operations | -99.62% | 9,809.91% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -125.06% | 732.84% | |||
| EBIT | 29.99% | -109.54% | |||
| EBITDA | 29.97% | -110.69% | |||
| EPS Basic | -122.87% | 1,053.17% | |||
| Normalized Basic EPS | 34.61% | -212.09% | |||
| EPS Diluted | -123.03% | 1,053.17% | |||
| Normalized Diluted EPS | 33.31% | -206.00% | |||
| Average Basic Shares Outstanding | 9.61% | -33.61% | |||
| Average Diluted Shares Outstanding | 7.44% | -32.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||